Flowvium
Zurück zum Explorer

CVS Health Corporation

CVSintermediary

CVS Health is one of the largest healthcare companies in the US, operating an integrated model spanning pharmacy benefits management (Caremark), health insurance (Aetna), retail pharmacy (9,900 stores), and primary care clinics (Oak Street Health, MinuteClinic).

Teilen:
Compare

Produkte & Umsatz

Umsatzanteil nach Produkt

Umsatzaufschlüsselung ($357B)

Statische Daten (Echtzeitfinanzen werden geladen…)

Health Services (Caremark PBM) (38%)
Health Insurance (Aetna) (35%)
Pharmacy & Consumer Wellness (22%)
Corporate / Other (5%)

Segmentzusammensetzung und Hauptkunden

Produktdetails

Pharmacy Benefits (CVS Caremark)38%

One of the three largest pharmacy benefit managers (PBMs) in the US. Manages drug coverage for 100M+ plan members.

Health Insurance (Aetna)35%

Aetna commercial, Medicare Advantage, and Medicaid health plans serving 24M+ members acquired for $69B in 2018.

Retail Pharmacy (CVS Pharmacy)22%

9,900+ retail pharmacy locations. Filling 1.5B+ prescriptions annually. Also includes front-store retail.

Health Services (MinuteClinic / Oak Street)5%

Primary care clinics (1,100+ MinuteClinics, 200+ Oak Street Health centers). Vertical integration into care delivery.

Makro- und Marktkontext

헬스케어Sektornachrichten

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Nächste Katalysatoren

CMS 메디케어 최종 수가 발표 (2026.Q2)UNH/HUM/CVS Q1 실적 (2026.04)IRA 약가 협상 2차 품목 공개

Aktuelle Nachrichten

Nachrichten laden...

KI-Analyse

Klicken Sie auf "KI-Analyse abrufen" für eine KI-gestützte Lieferkettenanalyse von CVS Health Corporation.

Unternehmensinformationen

Hauptsitz

Woonsocket, Rhode Island, USA

Gegründet

1963

Mitarbeiter

300,000+

Sektorübersicht헬스케어

Sektornachrichten

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Hauptthemen

  • CMS 메디케어 어드밴티지 수가 인하 → 보험사 마진 압박
  • AI 영상진단·병리학 도입 가속 — Tempus, Veracyte 수혜
  • GLP-1 보험 적용 확대 논의 → UNH·CVS 비용 증가 리스크

Nächste Katalysatoren

  • CMS 메디케어 최종 수가 발표 (2026.Q2)
  • UNH/HUM/CVS Q1 실적 (2026.04)